Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection.
Adult
B-Lymphocytes
/ metabolism
Child
Child, Preschool
Chronic Disease
Epstein-Barr Virus Infections
/ blood
Female
Flow Cytometry
/ methods
Herpesvirus 4, Human
/ metabolism
Humans
In Situ Hybridization, Fluorescence
/ methods
Killer Cells, Natural
/ metabolism
Lymphoproliferative Disorders
/ blood
Male
Phenotype
RNA, Viral
/ analysis
T-Lymphocytes
/ metabolism
Viral Load
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
02 11 2020
02 11 2020
Historique:
received:
30
11
2019
revised:
29
05
2020
accepted:
09
07
2020
entrez:
20
8
2020
pubmed:
20
8
2020
medline:
11
3
2021
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV) preferentially infects epithelial cells and B lymphocytes and sometimes T and NK lymphocytes. Persistence of EBV-infected cells results in severe lymphoproliferative disorders (LPDs). Diagnosis of EBV-driven T or NK cell LPD and chronic active EBV diseases (CAEBV) is difficult, often requiring biopsies. Herein, we report a flow-FISH cytometry assay that detects cells expressing EBV-encoded small RNAs (EBERs), allowing rapid identification of EBV-infected cells among PBMCs. EBV-infected B, T, and/or NK cells were detectable in various LPD conditions. Diagnosis of CAEBV in 22 patients of Caucasian and African origins was established. All exhibited circulating EBV-infected T and/or NK cells, highlighting that CAEBV is not restricted to native American and Asian populations. Proportions of EBV-infected cells correlated with blood EBV loads. We showed that EBV-infected T cells had an effector memory activated phenotype, whereas EBV-infected B cells expressed plasma cell differentiation markers. Thus, this method achieves accurate and unambiguous diagnoses of different forms of EBV-driven LPD and represents a powerful tool to study their pathophysiological mechanisms.
Identifiants
pubmed: 32812031
pii: 152032
doi: 10.1084/jem.20192262
pmc: PMC7596820
pii:
doi:
Substances chimiques
Epstein-Barr virus encoded RNA 1
0
Epstein-Barr virus encoded RNA 2
0
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 Fournier et al.
Déclaration de conflit d'intérêts
Disclosures: B. Terrier reported personal fees from AstraZeneca, GlaxoSmithKline, Roche/Chugai, and Vifor Pharma outside the submitted work. L. Galicier reported personal fees from Lilly and VIREOTEAM and nonfinancial support from EUSA Pharma, Overcome, and Janssen-Cilag outside the submitted work. No other disclosures were reported.
Références
Blood. 1996 Jan 15;87(2):839-41
pubmed: 8555511
Lancet Glob Health. 2016 Sep;4(9):e609-16
pubmed: 27470177
Curr Top Microbiol Immunol. 2015;390(Pt 1):119-48
pubmed: 26424646
Cell Host Microbe. 2017 Jul 12;22(1):61-73.e7
pubmed: 28704654
Nat Rev Cancer. 2004 Oct;4(10):757-68
pubmed: 15510157
Curr Protoc Cytom. 2016 Apr 01;76:7.46.1-7.46.8
pubmed: 27037579
Nat Immunol. 2003 Sep;4(9):815
pubmed: 12942076
Front Oncol. 2019 Feb 12;9:62
pubmed: 30809508
EMBO J. 2000 Jun 15;19(12):3080-9
pubmed: 10856251
Nat Microbiol. 2019 Dec;4(12):2475-2486
pubmed: 31501540
Life Sci. 1999;65(14):1433-53
pubmed: 10530796
J Immunol. 2003 Jun 15;170(12):5993-8
pubmed: 12794126
J Exp Med. 2017 Jan;214(1):73-89
pubmed: 28011863
Immunol Rev. 2019 Sep;291(1):174-189
pubmed: 31402499
Blood. 2019 Jun 27;133(26):2753-2764
pubmed: 31064750
Cancer Med. 2014 Aug;3(4):787-95
pubmed: 24799376
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8245-50
pubmed: 9653172
Proc Natl Acad Sci U S A. 1990 Nov;87(22):8790-4
pubmed: 2174165
J Clin Invest. 2006 Feb;116(2):322-33
pubmed: 16424938
PLoS Comput Biol. 2015 Jan 29;11(1):e1004077
pubmed: 25633866
Diagn Mol Pathol. 2004 Jun;13(2):61-8
pubmed: 15167006
Blood. 2012 Jan 19;119(3):673-86
pubmed: 22096243
Int J Hematol. 2017 Apr;105(4):406-418
pubmed: 28210942
Nat Microbiol. 2019 Mar;4(3):404-413
pubmed: 30664667
Blood. 2008 Feb 1;111(3):1420-7
pubmed: 17991806
Nature. 2014 Jun 12;510(7504):288-92
pubmed: 24870241
Blood. 2013 Oct 31;122(18):3101-10
pubmed: 23982171
J Exp Med. 1999 Aug 16;190(4):567-76
pubmed: 10449527
Front Pediatr. 2018 Nov 06;6:334
pubmed: 30460216
Immunity. 2002 May;16(5):745-54
pubmed: 12049725
Virology. 2015 Jan 1;474:117-30
pubmed: 25463610
J Exp Med. 2017 Feb;214(2):269-283
pubmed: 28108590
J Virol. 1998 Nov;72(11):9323-8
pubmed: 9765483
Blood. 2018 Jun 28;131(26):2899-2905
pubmed: 29712633
J Biol Chem. 2005 Oct 7;280(40):34133-42
pubmed: 16087662
Clin Cancer Res. 2011 May 1;17(9):2885-92
pubmed: 21478335
J Gen Virol. 2010 Jan;91(Pt 1):42-50
pubmed: 19793909
Haematologica. 2018 Jun;103(6):1018-1028
pubmed: 29242302
J Infect Dis. 2005 Nov 1;192(9):1505-12
pubmed: 16206064
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Open Forum Infect Dis. 2019 Apr 04;6(5):ofz171
pubmed: 31065564
Blood. 2008 Aug 1;112(3):672-9
pubmed: 18509091
Nature. 2011 Jul 27;475(7357):471-6
pubmed: 21796205
Cell Immunol. 2018 May;327:21-25
pubmed: 29499908
Front Pediatr. 2019 Mar 15;7:71
pubmed: 30931288
J Virol. 2004 May;78(10):5194-204
pubmed: 15113901
JCI Insight. 2017 Aug 17;2(16):
pubmed: 28814669
Cancer Sci. 2012 Aug;103(8):1481-8
pubmed: 22497716
Curr Opin Virol. 2013 Jun;3(3):227-32
pubmed: 23683686
Lancet Oncol. 2016 Mar;17(3):389-400
pubmed: 26873565
Proc Natl Acad Sci U S A. 1981 Feb;78(2):805-9
pubmed: 6262773
J Exp Med. 2019 Dec 2;216(12):2800-2818
pubmed: 31537641
J Infect Dis. 2009 Oct 1;200(7):1078-87
pubmed: 19698076
Front Oncol. 2018 Apr 30;8:139
pubmed: 29761078
Pathology. 2020 Jan;52(1):111-127
pubmed: 31767131
Front Pediatr. 2019 Feb 05;7:14
pubmed: 30805320
Front Immunol. 2018 Jun 04;9:1103
pubmed: 29942301
JCI Insight. 2020 Mar 12;5(5):
pubmed: 32161190